PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

and to a collection of information unless it dis	plays a valid OMB contlot numbe
Application Number	"0
Filing Date	February 13,2004
First Named Inventor	Shangold et a 🕳 🚞
Group Art Unit	77
Examiner Name	40 2
Attorney Docket Number	ORT-1373

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
7		A.M. KAUNITZ; "Efficacy, Cycle Control, and Safety of Two Triphasic Oral Contraceptives: Cyclessa (Desogestrel/Ethinyl Estradiol) and Ortho-Novum 7/7/7 (Norethindrone/Ethinyl Estradiol) pp 295-302	

			<u> </u>

Examiner	100	Date	6121/11	
Signature		Considered	· · · · · · · · · · · · · · · · · · ·	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office. Washington, DC 20231

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

AUG 2 0 2001

SUBMISSION UNDER MPEP 609 D

Application Number 09/782,420
Filing Date February 13, 2001
First Named Inventor Shangold et al
Group Art Unit
Examiner Name
Attorney Docket Number ORT-1373

Page 1 of 1

U.S. PATENT DOCUMENTS U.S. Patent Document Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² where relevant passages or relevant figures appear Cite Examiner of Cited Document Initials (if known) Number No.1 FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, where relevant passages Foreign Patent Document Name of Patentee or or relevant figures Т Examiner Cite Applicant of Cited Document KindCode5 appear Office³ Number⁴ Initials No.1 00/38691 wo Α1 Search report Ortho-McNeil Pharmaceutical, Inc. OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published T^2 Cite Examiner No.1 Initials*

Examiner	uQ+	Date	11 MINI	
Signature	109	Considered	000000	



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resp ollection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

JOHN TO A CONCORDER OF WHICH HIGH AT A LOCAL	plays a valid Givis control flambor.
Application Number	09/782,420
Filing Date	February 13, 2001
First Named Inventor	Shangold et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1373

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No. ¹	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
1		4,066,757		Pasquale	01/03/1978	424/243
4		3,795,734		Rochefort	03/05/1974	424/238
6		2,431,704		Musher	12/02/1947	99/136
0		4,390,531		Edgren	06/28/1983	4241239
9		3,957,982		Ursula Lachnit-Fixson	05/18/1976	4241238
D		4,530,839		Pasquale	07/23/1985	514/171
5		4,544,554		Pasquale	10/01/1985	5141170
4		4,616,006		Pasquale	10/07/1986	514 1170
٥		4,628,051		Pasquale	12/09/1986	511/170
3						

				FO	REIGN PATENT DOCUMENTS					
		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Name of Patentee or of Cited Document where relevan			
Initiale	Cite No. ¹	Office ³	Number⁴	KindCode ⁵		T⁵				
10		EP	0491415	A1	AKZO N.V.	06/24/1992				
						·		igspace		
							,			

Examiner Signature	Date Considered	HAAA	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer____ DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for February, Washington, DC 20231.

AUG 2 2 2001

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respon to a collection of information unless it displays a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

ond to a confection of information unless it disp	nayo a tana onto contaci nambor.
Application Number	09/782,420
Filing Date	February 13, 2001
First Named Inventor	Shangold et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	ORT-1373

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
No.1	publisher, city and/or country where published	
	0.150 mg DESOGESTREL In Combination with 0.020 mg OR 0.030 mg ETHINYLESTRADIOL, Acta Obstet Gynecol Scand,	
	AKERLUND, M.; A. RODE; A ND J. WESTERGAARD, Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150μg desogestrel and either 30 μg or 20μg ethinyl oestradiol; Brit Journal Obstet and Gynecol; Vol. 100. Sept 1993, pp. 832-838	
	J. ENDRIKAT, U. MULLER, AND B. DUSTERBERG; A Twelve-Month Comparative Clinical Investigation of Two Low-Dose Oral Contraceptives Containing 20 μg Ethinylestradiol/75 μg Gestodene, with Respect to Efficacy, Cycle Control, and Tolerance: Contraception 1997:55:131-137	
	KOETSAWANG AND KIRIWAT ET AL, A Randomized, Double-Blind Study of Six Combined Oral Contraceptives, March 1982 Vol 25 No. 3	
	to a New Triphasic Contraceptive-I Chemistry Profiles XP-000881634	
	B.E. SCHWARZ,MD Reference Period Analysis of Vaginal Bleeding with Triphasic ORal Contraceptive Agents Containing Norethindrone or Levonorgestrel: A Comparison Study XP-000881622, PP 176-182	
		i
		<u> </u>
		<u> </u>
		
_		-
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published TUIMALA, R.; M. SARANEN; AND U. ALAPIESSA, A Clinical Comparison in Finland of Two Oral Contraceptives Containing 0.150 mg DESOGESTREL in Combination with 0.020 mg OR 0.030 mg ETHINYLESTRADIOL, Acta Obstet Gynecol Scand, Vol.144, 1988 pages 7-12 AKERLUND, M.; A. RODE; A ND J. WESTERGAARD, Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150µg desogestrel and either 30 µg or 20µg ethinyl oestradiol; Brit Journal Obstet and Gynecol; Vol. 100, Sept 1993, pp. 832-838 J. ENDRIKAT, U. MULLER, AND B. DUSTERBERG; A Twelve-Month Comparative Clinical Investigation of Two Low-Dose Oral Contraceptives Containing 20 µg Ethinylestradiol/75 µg Gestodene, with Respect to Efficacy, Cycle Control, and Tolerance; Contraception 1997;55:131-137 KOETSAWANG AND KIRIWAT ET AL, A Randomized, Double-Blind Study of Six Combined Oral Contraceptives, March 1992 Vol 25 No. 3 C.D. LOX Gen. Pharmac. Vol. 27, No. 2, pp 367-370, 1996, Biochemical Effects in Women Following One Year's Exposure to a New Triphasic Contraceptive-I Chemistry Profiles XP-000881634 B.E. SCHWARZ,MD Reference Period Analysis of Vaginal Bleeding with Triphasic ORal Contraceptive Agents Containing Norethindrone or Levonorgestrel: A Comparison Study XP-000881622, PP 176-182

Examiner Signature	Date Considered	11/19/21

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

TECH CENTER 1600/2900

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE CITATION O THE ANY APPLICATION AUG 2 0 2001

	Sneet 1 of :
Docket No.	Serial No.
ORT-1009	09/328,764
Applicant	

Gary Shangold et al

Filing Date

Group Art Unit

June 9, 1999

1614

U.S. PATENT DOCUMENTS

Exam'r						
Init.	Document No.	Date	Name	Class	Sub	Pilo Dana
					Class	File Date
				ļ		
······································	 					
				<u> </u>		
				ļ		
		 				
						<u> </u>

FOREIGN PATENT DOCUMENTS

Exam'r		T =====					
Init.	Document No.	Date	Country	Class	Sub Class	Translate (select one)	
	0 491 415 A1	5/12/91	EP			Yes	No
				A61K 31	565		
	<u> </u>		:				l
						4	
						7	
	<u></u>	1				1 ''] 🖰

OTHER REFERENCES (include author, title, date, pertinent pages, etc.)

	,	Scwarz B E ET AL: "Reference period analysis-of vaginal bleeding with-triphasic oral contraceptive agents containing norethindrone or levonorgestrel: a comparison study." page 178; table 1 page 181
	 -	Lox-C-D;Biochemical-offcare
		contraceptive-I. Chemistry profiles. General Pharmacology, (1996 Mar 27 (2) 367-70.,
·		

Examiner:		Date Considered	
Examiner: Initial if citation	considered, whether or not cital	10107	
11 Not In conformance and not	considered. Include copy of this	tion is in confirmance with MPEP \$609; Draw l s form with next communication to the applica	ine through citation

Form PTO-1449

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

Docket No.	Serial No.				
ORT-1009	09/328,764				
Applicant					
Gary Shangold et al.					
Filing Date	Grand No.				
55	Group Art Unit				

1614

U.S. PATENT DOCUMENTS

June 9, 1999

Exam'r Init.	Document No.	Date	Name	Class	Sub	7/1- 2-4
<u>O</u>	4,530,839	7/23/85	Samuel A. Pasquale		Class	File Date
9	4,544,554	10/1/85	Samuel A. Pasquale	514	171	9/26/83
5	4,616,006	10/7/86		514	170	5/4/84
b	4,628,051	12/9/86	Samuel A. Pasquale	514	170	6/13/85
Ā	3,957,982		Samuel A. Pasquale	514	170	6/11/85
B	4,291,028	5/18/76	Ursula Lachnit-Fixson	424	238	12/23/74
	·	9/22/81	Nichols Vorys	424	238	10/11/79
<u>B</u>	4,378,356	3/29/83	Evert de Jager	424	238	3/16/81
	4,390,531	6/28/83	Richard A. Edgren	424	239	8/10/81
<u> </u>	4,948,593	8/14/90	J.D. Wright et al.	424	473	5/15/89
<u> </u>	4,962,098	9/9/90	R.M. Boissonneault	514	170	4/20/89
<u></u>	5,418,228	5/23/95	Herman J.T.C. Bennink	514	182	
P	5,262,408	11/16/93	Engelhart W. Bergink	514	182	1/14/94
				-	102	12/12/91
Δ_	3,568,828	3/9/71	Leonard J. Lerner	205		Entity.
Q	3,836,651	9/17/74	Harry Rudel	206	42	3/1/67
b	3,932,635	1/13/76	Eugene J. Segre	424	239	2/22/72
5	3,939,264	2/17/76		424	239	5/5/72
0	3,969,502		Ursala Lachnit-Fixson	424	239	4/12/73
		7/13/76	Ursala Lachnit-Fixson	424	239	7/9/74
Ь	5,585,370	 				1.2.
D		12/7/96	Robert F. Casper	514	170	12/5/94
	5,747,480	5/5/98	Michael J. Gast	514	179	4/17/97
<i>•</i>	5,023,084	6/11/91	Yie W. Chien	424	448	12/16/88
<u>D</u>	5,453,279	9/26/95	Chia-Shun Lee et al.	424	448	4/21/92
<u></u> <u></u>	4,921,843	5/1/90	Samuel A. Pasquale	514	170	10/20/88
$\boldsymbol{\rho}$	Re. 35,724	2/3/98	Samuel A. Pasquale			/40/08

11/19/01

Examiner: Initial if citation considered, whether or not citation is in confirmance with MPEP \$609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.